ESC 365 - Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - PRO.

ACVC Premium Access

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - PRO.

Session: Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic?

Topic: Acute Coronary Syndromes

Speaker: Professor R. Welsh (Edmonton, CA)

Event: ACVC 2021

Congress Presentation

About the speaker

Professor Robert Welsh

Mazankowski Alberta Heart Institute, Edmonton (Canada)

15 presentations

0 follower

5 more presentations in this session

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – PRO.

Speaker: Professor K. Huber (Vienna, AT)

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – CON.

Speaker: Professor C. Granger (Durham, US)

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – Discussion.

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - CON.

Speaker: Professor A. Kastrati (Munich, DE)

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - Discussion.

Access the full session

Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic?

Speakers: Professor R. Welsh, Professor K. Huber, Professor C. Granger, Professor A. Kastrati

About the event

ACVC 2021

13 March - 14 March 2021

Sessions Presentations

Congress

Related content

Open Access

Introduction & relevance of INOCA.

28 August 2021

Open Access

New recommendations for the treatment of HFrEF.

27 August 2021

Open Access

GUIDE-HF - Panel discussion.

27 August 2021

ESC 365 is supported by